Thursday, February 5, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Earnings

Synopsys Shares Plunge Following Disappointing Earnings Report

Andreas Sommer by Andreas Sommer
September 20, 2025
in Earnings, Semiconductors, TecDAX, Tech & Software
0
Synopsys Stock
0
SHARES
119
VIEWS
Share on FacebookShare on Twitter

Semiconductor design software leader Synopsys witnessed its most severe single-day stock decline in history on September 9th. The company’s shares plummeted nearly 36% following the release of quarterly results that fell short of expectations and prompted a significant reduction in full-year guidance.

Earnings Miss and Guidance Reduction Spark Selloff

While Synopsys reported a 14% year-over-year revenue increase to $1.74 billion for the quarter, these figures failed to meet analyst projections. More concerning to investors was the decline in adjusted earnings per share, which dropped to $3.39, also missing market expectations.

The most significant weakness emerged in the company’s Design IP segment, where revenues contracted by 7.7%. Company leadership attributed this underperformance to three primary factors: weakened customer demand, ongoing export restrictions, and substantial operational challenges with a major foundry partner. The strength in Synopsys’s Design Automation business was insufficient to offset these headwinds.

Revised Outlook Intensifies Investor Concerns

Compounding the disappointing quarterly performance, management substantially lowered its financial outlook for fiscal year 2025. The company now anticipates adjusted earnings per share in the range of $12.76 to $12.80, representing a notable reduction from previous targets.

Should investors sell immediately? Or is it worth buying Synopsys?

Key developments driving the market reaction:
* Historic single-day decline of approximately 36%
* Design IP segment revenue decline of 7.7%
* Significant reduction in full-year adjusted EPS guidance
* Operational challenges with key foundry partner

Analyst Community Responds to Deteriorating Outlook

Wall Street analysts moved quickly to adjust their positions following the report. Needham reduced its price target from $660 to $550, while Rosenblatt downgraded the stock from “Buy” to “Neutral” and lowered its target from $650 to $605. JPMorgan Chase similarly decreased its price objective from $685 to $600.

Adding to the company’s challenges, a law firm has announced investigations into whether Synopsys may have misled investors regarding customer-related risks. This development suggests potentially lasting damage to investor confidence in the company’s disclosures.

Ad

Synopsys Stock: Buy or Sell?! New Synopsys Analysis from February 5 delivers the answer:

The latest Synopsys figures speak for themselves: Urgent action needed for Synopsys investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 5.

Synopsys: Buy or sell? Read more here...

Tags: Synopsys
Andreas Sommer

Andreas Sommer

About Andreas Sommer Over 40 years of expertise in market analysis, chart technical analysis, and strategic investment advisory. With more than four decades of experience in banking and financial journalism, Andreas Sommer is recognized as one of the leading analysts in the German-speaking market. His deep understanding of market dynamics and technical analysis has helped countless investors navigate complex financial markets.
Areas of Expertise:
  • Technical Chart Analysis
  • Strategic Investment Advisory
  • Market Trend Analysis
  • Financial Journalism
Andreas brings unparalleled insights from his extensive career in banking and financial markets, making him a trusted voice for investors seeking professional guidance.

Related Posts

EOS Stock
Defense & Aerospace

Strategic Robotics Partnership Signals New Growth Phase for EOS Defence

February 5, 2026
NexPoint Residential Stock
Dividends

NexPoint Residential Trust Sets Date for Annual and Q4 2025 Results

February 4, 2026
PC Connection Stock
Earnings

PC Connection Set to Report Full-Year and Fourth Quarter Earnings

February 4, 2026
Next Post
Microsoft Stock

Microsoft's Multi-Billion Dollar Bet on AI Infrastructure

Coinbase Stock

Coinbase Stock Surges as DeFi Expansion Captures Market Momentum

Arvinas Stock

Arvinas Announces Major Strategic Overhaul Amid Restructuring

Recommended

Oracle Stock

Oracle Shares Plunge as Investor Confidence Evaporates

3 months ago
Home Construction Trading online

Analyst Initiates Coverage on Installed Building Products with Buy Rating and 275 Price Target

2 years ago
Applied Materials Stock

Applied Materials: Navigating Market Volatility Amid AI-Driven Semiconductor Demand

5 months ago
Amazon Stock

Amazon’s Aggressive AI Expansion: Balancing Massive Investment with Market Expectations

2 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

PC Connection Set to Report Full-Year and Fourth Quarter Earnings

Fossil Group Stock Surges Past Key Technical Threshold

NextGen Healthcare: Strategic Wins and Industry Accolades Signal Sustained Momentum

Arcus Biosciences Pivots Pipeline Strategy Following Clinical Setback

National Healthcare’s Financial Report: A Crucial Test Approaches

XRP’s Dual Milestone: Regulatory Green Light Meets Core Protocol Upgrade

Trending

CureVac Stock
Mergers & Acquisitions

CureVac Delisted Following BioNTech Acquisition Completion

by Andreas Sommer
February 5, 2026
0

The chapter for CureVac as an independent publicly traded company has officially closed. The biotech firm's shares...

EOS Stock

Strategic Robotics Partnership Signals New Growth Phase for EOS Defence

February 5, 2026
NexPoint Residential Stock

NexPoint Residential Trust Sets Date for Annual and Q4 2025 Results

February 4, 2026
PC Connection Stock

PC Connection Set to Report Full-Year and Fourth Quarter Earnings

February 4, 2026
Fossil Stock

Fossil Group Stock Surges Past Key Technical Threshold

February 4, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • CureVac Delisted Following BioNTech Acquisition Completion
  • Strategic Robotics Partnership Signals New Growth Phase for EOS Defence
  • NexPoint Residential Trust Sets Date for Annual and Q4 2025 Results

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com